New Delhi, 22 Feb 2025: Since 2022, government officials have carried out risk-based inspections at over 500 pharmaceutical manufacturing facilities, with sources indicating that these evaluations will persist as part of India's initiative to enhance the quality of domestically p......
View Details

Related News

• Export NOCs, permission to manufacture and not approved by the importing country for combination of Tapentadol and Carisoprodol are revoked (22-02-2025)

---

• DCA Telangana cracks down on overpricing and misleading drug claims (22-02-2025)

---

• DCA busts unlicensed manufacturing drugs unit in Sangareddy (22-02-2025)

---

• A committee formed in Dehradun, to address the issue of companies producing counterfeit medications (22-02-2025)

---

• BioAsia 2025 to host Global Healthcare Leaders to drive transformative innovation (22-02-2025)

---

• Bihar Takes Firm Stance Against Counterfeit Medicines, Health Secretary Issues Strong Directives (22-02-2025)

---

• Bombay HC Quashes Income Tax Reassessment Notice Against Lupin Ltd For AY 2016-17 (22-02-2025)

---

• Govt extends Rajeev Singh Raghuvanshi's tenure as DCGI by one year (22-02-2025)

---

• CrisprBits develops PathCrisp for detection of AMR (22-02-2025)

---

• Medicines valued at Rs 2 lakh confiscated from Hans Foundation Chhabra office (21-02-2025)

---